Ernexa Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Ernexa Therapeutics Inc. (ERNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period of 58.00 thousand shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod · last filed 2021-03-11
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2019-06-30 was 7.00K shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2019-03-31 was 4.00K shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-12-31 was 4.00K shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for the quarter ending 2018-09-30 was 9.00K shares.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2020 was 58.00K shares, a 52.63% increase from fiscal 2019.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2019 was 38.00K shares, a 192.31% increase from fiscal 2018.
- Ernexa Therapeutics Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period for fiscal 2018 was 13.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 12 month |
|---|---|---|---|---|
| 2020-12-31 | 58.00K shares 10-K · filed 2021-03-11 | |||
| 2019-12-31 | 38.00K shares 10-K · filed 2021-03-11 | |||
| 2019-06-30 | 7.00K shares 10-Q · filed 2019-08-12 | 11.00K shares 10-Q · filed 2019-08-12 | 15.00K shares derived: sum of 3 quarters · filed 2020-03-19 | 24.00K shares derived: sum of 4 quarters · filed 2020-03-19 |
| 2019-03-31 | 4.00K shares 10-Q · filed 2019-05-14 | 8.00K shares derived: sum of 2 quarters · filed 2020-03-19 | 17.00K shares derived: sum of 3 quarters · filed 2020-03-19 | |
| 2018-12-31 | 4.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | 13.00K shares derived: sum of 2 quarters · filed 2020-03-19 | 13.00K shares 10-K · filed 2020-03-19 | |
| 2018-09-30 | 9.00K shares 10-Q · filed 2018-11-09 | 9.00K shares 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |